GEN Exclusives

More »

GEN News Highlights

More »
Oct 5, 2009

GVK Biosciences and Quantitative Solutions to Market Clinical Trial Outcome Databases

  • GVK Biosciences and Quantitative Solutions (QS) entered a strategic partnership to develop and market clinical trial outcome databases. The databases will be designed to capture summary-level data for the clinical safety and efficacy outcomes from publicly available data sources.

    GVK BIO will distribute globally existing QS databases in five indications immediately: rheumatoid arthritis and psoriasis, chronic HCV, neuropathic pain, osteoporosis (postmenopausal), and major depression. GVK BIO and QS plan to jointly develop and market additional databases in dyslipidemia, schizophrenia, alzheimer’s, and other indications in the near future.

    The aim is for the clinical trial outcome databases to assist drug development teams to conduct comparative efficacy and safety analysis, link/scale biomarkers to clinical outcomes, predict/improve trial outcome, and develop product differentiation strategies. The databases will be supported by customization and M&S consulting services provided by GVK BIO and QS, respectively.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?